Digoxin concentrations in serum and cantharides blister fluid: correlations with cardiac response. 1987

M Schäfer-Korting, and G G Belz, and J Brauer, and R G Alken, and E Mutschler
Pharmakologisches Institut für Naturwissenschaftler der Universität, Frankfurt, F.R.G.

The relationship between the pharmacokinetics and dynamics of digoxin was investigated using a skin blistering technique that allows experimental access to tissue fluid concentrations. Eight healthy volunteers received digoxin, 1.0 mg, and placebo intravenously according to a double-blind crossover design. Drug concentrations were determined during a 72-hour period in serum, urine, and cantharides blister fluid (CBF). Digoxin levels in the hypothetic peripheral compartments were calculated from serum concentrations. Digoxin effects (total electromechanical systole [QS2c], left ventricular ejection time [LVETc], preejection period [PEPc], QTc time, heart rate, and T wave amplitude) were measured simultaneously. Peak levels in the shallow and deep compartments occurred at 12 1/2 to 20 minutes and 3 hours and the maximum concentration in CBF (2.75 +/- 0.48 ng/ml) occurred at 1 hour. Digoxin effects on QS2c, PEPc, and the ratio PEP/LVET were not related to serum concentrations but were closely related to CBF concentrations (r = 0.90). CBF concentrations were then within the range of serum digoxin concentrations usually associated with the treatment of heart failure. Thus, CBF allows experimental access to active drug concentrations after a single intravenous dose.

UI MeSH Term Description Entries
D008297 Male Males
D001768 Blister Visible accumulations of fluid within or beneath the epidermis. Bulla,Vesication,Bleb,Bullae,Bullous Lesion,Blebs,Blisters,Bullous Lesions,Lesion, Bullous,Lesions, Bullous,Vesications
D004077 Digoxin A cardiotonic glycoside obtained mainly from Digitalis lanata; it consists of three sugars and the aglycone DIGOXIGENIN. Digoxin has positive inotropic and negative chronotropic activity. It is used to control ventricular rate in ATRIAL FIBRILLATION and in the management of congestive heart failure with atrial fibrillation. Its use in congestive heart failure and sinus rhythm is less certain. The margin between toxic and therapeutic doses is small. (From Martindale, The Extra Pharmacopoeia, 30th ed, p666) Digacin,Digitek,Digoregen,Digoxina Boehringer,Digoxine Nativelle,Dilanacin,Hemigoxine Nativelle,Lanacordin,Lanicor,Lanoxicaps,Lanoxin,Lanoxin-PG,Lenoxin,Mapluxin,Boehringer, Digoxina,Lanoxin PG,Nativelle, Digoxine,Nativelle, Hemigoxine
D004562 Electrocardiography Recording of the moment-to-moment electromotive forces of the HEART as projected onto various sites on the body's surface, delineated as a scalar function of time. The recording is monitored by a tracing on slow moving chart paper or by observing it on a cardioscope, which is a CATHODE RAY TUBE DISPLAY. 12-Lead ECG,12-Lead EKG,12-Lead Electrocardiography,Cardiography,ECG,EKG,Electrocardiogram,Electrocardiograph,12 Lead ECG,12 Lead EKG,12 Lead Electrocardiography,12-Lead ECGs,12-Lead EKGs,12-Lead Electrocardiographies,Cardiographies,ECG, 12-Lead,EKG, 12-Lead,Electrocardiograms,Electrocardiographies, 12-Lead,Electrocardiographs,Electrocardiography, 12-Lead
D005260 Female Females
D006321 Heart The hollow, muscular organ that maintains the circulation of the blood. Hearts
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D013599 Systole Period of contraction of the HEART, especially of the HEART VENTRICLES. Systolic Time Interval,Interval, Systolic Time,Intervals, Systolic Time,Systoles,Systolic Time Intervals,Time Interval, Systolic,Time Intervals, Systolic

Related Publications

M Schäfer-Korting, and G G Belz, and J Brauer, and R G Alken, and E Mutschler
January 1958, Deutsches Archiv fur klinische Medizin,
M Schäfer-Korting, and G G Belz, and J Brauer, and R G Alken, and E Mutschler
January 1992, European journal of clinical pharmacology,
M Schäfer-Korting, and G G Belz, and J Brauer, and R G Alken, and E Mutschler
April 1952, Bollettino della Societa italiana di biologia sperimentale,
M Schäfer-Korting, and G G Belz, and J Brauer, and R G Alken, and E Mutschler
January 1950, Annali italiani di dermatologia e sifilografia,
M Schäfer-Korting, and G G Belz, and J Brauer, and R G Alken, and E Mutschler
January 1955, Archiv fur klinische und experimentelle Dermatologie,
M Schäfer-Korting, and G G Belz, and J Brauer, and R G Alken, and E Mutschler
April 1984, International journal of clinical pharmacology, therapy, and toxicology,
M Schäfer-Korting, and G G Belz, and J Brauer, and R G Alken, and E Mutschler
October 1982, European journal of clinical pharmacology,
M Schäfer-Korting, and G G Belz, and J Brauer, and R G Alken, and E Mutschler
January 1981, Antimicrobial agents and chemotherapy,
M Schäfer-Korting, and G G Belz, and J Brauer, and R G Alken, and E Mutschler
January 1953, Archiv fur Dermatologie und Syphilis,
M Schäfer-Korting, and G G Belz, and J Brauer, and R G Alken, and E Mutschler
March 1958, Dermatologische Wochenschrift,
Copied contents to your clipboard!